My biggest takeaway from this is that Graham says Novartis are looking to bring their product to market by the end of the year? And that product works infinitely better with Veyonda. So are we to take from that we could have a drug on market by years end? That is far beyond what I had expected, or even thought possible?
If this is the case, I do wonder if Novartis just buy us out now and move ahead with getting that combined drug to market themsevles.
Am I missing something?!
My biggest takeaway from this is that Graham says Novartis are...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $11.41K | 108.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123424 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |